<iframe src="https://www.googletagmanager.com/ns.html?id=GTM-5FCBM4B" height="0" width="0" style="display:none;visibility:hidden">


Latest news and updates about the Medicare and pharmacy industries.

Omnicell Completes Acquisition of FDS Amplicare

Posted on September 13, 2021 by FDS Amplicare Team

Addition of SaaS solutions accelerates EnlivenHealth’s innovation roadmap to help retail pharmacies forecast and reduce DIR fees

MOUNTAIN VIEW, Calif. — September 9, 2021 — Omnicell, Inc. (NASDAQ:OMCL), a leading provider of medication management solutions and adherence tools for health systems and pharmacies, today announced that it has completed the previously announced acquisition of FDS Amplicare. The acquisition adds a comprehensive and complementary suite of SaaS financial management, analytics, and population health solutions to Omnicell’s EnlivenHealth™ division.

EnlivenHealth is an industry-leading provider of patient engagement solutions for retail pharmacies and health plans. EnlivenHealth’s mission is to build and orchestrate advanced digital solutions that help its customers to measurably improve patient health outcomes while enabling new clinical services that drive growth and profitability. The addition of FDS Amplicare’s differentiated financial management, analytics, and population health solutions, along with its nationwide network of more than 15,000 independent retail pharmacies, expands EnlivenHealth’s broad industry footprint while complementing the EnlivenHealth offering and mission.

“The digitization of virtually every aspect of healthcare and the COVID-19 pandemic have accelerated fundamental shifts in how, where, and when care is delivered, with retail pharmacies at the forefront of these historic changes,” said Randall Lipps, chairman, president, CEO, and founder of Omnicell. “By combining EnlivenHealth’s strong patient engagement and clinical capabilities with FDS Amplicare’s widely deployed financial and analytics solutions, we are even better positioned to strengthen the health of our retail pharmacy and health plan customers and the patient populations they serve.”

Accelerates DIR Mitigation Solution Roadmap and Leadership

Direct & Indirect Remuneration (DIR) fees continue to challenge the business health of the retail pharmacy industry, especially independent pharmacies. FDS Amplicare’s industry-leading financial management, analytics, and Medicare plan selection solutions are important components that are helping retail pharmacies to manage, forecast, and mitigate their DIR fee exposure. Combined with EnlivenHealth’s proven clinical and data science capabilities, this differentiated, multi-pronged offering is designed to enable retail pharmacies to bend the DIR growth curve.

Under the terms of the purchase agreement, the acquisition price was $177 million, subject to customary adjustments. The FDS Amplicare business that is being acquired recorded approximately $29 million in total revenue (unaudited) for the 12 months ended June 30, 2021. Omnicell used available cash on its balance sheet to finance the transaction, which is expected to be immediately accretive to Omnicell’s non-GAAP EBITDA and non-GAAP Earnings per share.

“With the addition of these new capabilities, EnlivenHealth now offers the industry’s most comprehensive suite of digital technology solutions that are proven to help retail pharmacies and health plans grow and succeed in the new digital-driven era of healthcare,” said Scott Seidelmann, executive vice president and chief commercial officer, Omnicell. “We are thrilled to welcome our new colleagues from FDS Amplicare to the Omnicell/EnlivenHealth family. We look forward to working with them to advance our shared vision of being the most trusted partner for pharmacies and health plans to ensure the lifelong, optimal health of patients.”

Additional details of this acquisition are included in an investor presentation found in the Investor Relations section of Omnicell's website, www.omnicell.com.


About Omnicell
Since 1992, Omnicell has been committed to transforming the pharmacy care delivery model to dramatically improve outcomes and lower costs. Through the vision of the autonomous pharmacy, a combination of automation, intelligence, and technology-enabled services, powered by a cloud data platform, Omnicell supports more efficient ways to manage medications across all care settings. Over 7,000 facilities worldwide use Omnicell automation and analytics solutions to help increase operational efficiency, reduce medication errors, deliver actionable intelligence, and improve patient safety. More than 50,000 institutional and retail pharmacies across North America and the United Kingdom leverage Omnicell’s innovative medication adherence and population health solutions to improve patient engagement and adherence to prescriptions, helping to reduce costly hospital readmissions. To learn more, visit www.omnicell.com.

Other Articles

Posted on March 12, 2019
by Amplicare Team

Amplicare and Ananda Professional Partner to Automate CBD and Wellness Education for Pharmacies

Amplicare and Ananda Professional are excited to announce a partnership to expand pharmacy access to CBD and wellness education through automation...

Continue Reading
Posted on November 5, 2020
by Amplicare Team

FDS and Amplicare Drive Significant Return for Customers and Increase Market Leadership, Ushering in the New Era of Pharmacy

FDS, Inc. and Amplicare today announce significant growth and customer milestones, marking the dawn of a new era in the pharmacy market.

Continue Reading
Posted on October 7, 2020
by Amplicare Team

FDS and Amplicare Launch Navigate™, an Online Enrollment Platform to Help Pharmacies and Patients Remotely Collaborate on Medicare Comparisons and Enrollment

Navigate empowers pharmacists to improve the shopping experience for Medicare beneficiaries during Medicare’s annual Open Enrollment Period

Continue Reading
Posted on June 25, 2020
by Amplicare Team

A Message from Amplicare’s Leadership

As we reflect on the events of the past month, Amplicare is committed to promoting diversity, inclusion, and equity, within our company and beyond.

Continue Reading